目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T29198 | |||
Z060228 is an potent anti-HBV inhibitor. The HBV DNA replication was effectively inhibited by Z060228 in the supernatants of the HepG2.2.15 cells. Z060228 exhibited effects on the self-assembly of Cp149. SEC data revealed that Z060228 altered the equilibr | |||
T81531 | |||
Pedunculosumoside F,一种从Ophioglossum pedunculosum分离得到的同型黄酮苷,对HepG2 2.2.15细胞表现出细胞毒性,其CC50值为56.7 μM,但缺乏抗HBV活性。然而,其类似物能够抑制HBV感染的HepG2 2.2.15细胞中HBsAg的分泌。 | |||
T69925 | |||
NVR 3-778 is the first capsid assembly modulator (CAM) that has demonstrated antiviral activity in hepatitis B virus (HBV)-infected patients. NVR 3-778 inhibited the generation of infectious HBV DNA-containing virus particles with a mean antiviral 50% effective concentration (EC50) of 0.40 µM in HepG2.2.15 cells. The antiviral profile of NVR 3-778 indicates pan-genotypic antiviral activity and a lack of cross-resistance with nucleos(t)ide inhibitors of HBV replication. | |||
T26756 | |||
BCM-599 is a HBV capsid assembly inhibitor. BCM-599 showed IC50 of 0.88 μM and CC50 of 144 μM in HepG2.2.15 cells. | |||
T26741 | |||
BAY38-7690, a hepatitis B virus inhibitor, may have potential for future therapeutic regimens to combat chronic HBV infection. | |||
T72884 | |||
trans-ccc_R08 是一种有效的cccDNA(共价闭合环状 DMA) 抑制剂。trans-ccc_R08 抑制 HBeAg 水平,IC50值为 0.08 µM。\trans-ccc_R08 具有研究乙型肝炎病毒 (HBV) 感染的潜力。 | |||
T72324 | |||
Lagociclovir valactate 是 Lagociclovir 的前药。Lagociclovir valactate 是一种具有口服活性的抗HBV 试剂。 | |||
T11549 | Others | ||
Helioxanthin 8-1, an analogue of helioxanthin, exhibits significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 μM. | |||
T40120 | |||
FNC-TP, the intracellular active form of FNC, is a potent nucleoside reverse transcriptase inhibitor (NRTI) with broad-spectrum antiviral activity against HIV, HBV, and HCV. | |||
T60285 | |||
L-2'-Fd4C 是一种L-核苷类似物,具有抗人类免疫缺陷病毒 (HIV) 和抗乙型肝炎病毒 (HBV) 活性。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPK-01492 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPK-01501 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi) | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPK-01491 | HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated | Human | HEK293 Cells | ||
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7).
|
|||||
TMPY-05822 | Hepatitis B Virus (HBV)(ayw/France/Tiollais/1979) Capsid protein (His) | HBV-D | E. coli | ||
Hepatitis B virus (HBV) capsid assembly is a critical step in the propagation of the virus and is mediated by the core protein. The first cytoplasmic step in the formation of an infectious HBV virion is the formation of a capsid containing pregenomic RNA (pgRNA) and the viral polymerase (Pol). HBV capsid assembly is an attractive target for new antiviral therapies.
|
|||||
TMPH-00803 | HBV-A subtype adw2 (strain Rutter 1979) Capsid protein (His) | HBV-A | E. coli | ||
HBV-A subtype adw2 (strain Rutter 1979) Capsid protein (His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 25.4 kDa and the accession number is P03148.
|
|||||
TMPH-00807 | HBV-D subtype ayw (isolate France/Tiollais/1979) Protein X (His & SUMO) | HBV-D | E. coli | ||
HBV-D subtype ayw (isolate France/Tiollais/1979) Protein X (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 32.6 kDa and the accession number is P03165.
|
|||||
TMPH-00806 | HBV-D (isolate Germany/1-91/1991) Protein X (His & SUMO) | HBV-D | E. coli | ||
HBV-D (isolate Germany/1-91/1991) Protein X (His & SUMO) is expressed in E. coli expression system with N-6xHis-SUMO tag. The predicted molecular weight is 32.7 kDa and the accession number is O93195.
|
|||||
TMPH-00816 | HBV-A subtype adw2 (strain Rutter 1979) Large envelope protein (His) | HBV-A | E. coli | ||
HBV-A subtype adw2 (strain Rutter 1979) Large envelope protein (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 45.1 kDa and the accession number is P03141.
|
|||||
TMPH-00808 | HBV-D subtype ayw (isolate Japan/JYW796/1988) Protein X (His) | HBV-D | E. coli | ||
HBV-D subtype ayw (isolate Japan/JYW796/1988) Protein X (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 22.6 kDa and the accession number is Q9QMI3.
|
|||||
TMPH-00815 | HBV-A subtype adw2 (isolate Germany/991/1990) Capsid protein (His & Myc) | HBV-A | E. coli | ||
HBV-A subtype adw2 (isolate Germany/991/1990) Capsid protein (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 28.9 kDa and the accession number is P0C693.
|
|||||
TMPH-00804 | HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (Yeast, His) | HBV-C | P. pastoris (Yeast) | ||
HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (Yeast, His) is expressed in yeast with N-6xHis tag. The predicted molecular weight is 23.0 kDa and the accession number is P0C6H7.
|
|||||
TMPH-00805 | HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (E. coli, His) | HBV-C | E. coli | ||
HBV-C subtype ayw (isolate China/Tibet127/2002) Capsid protein (E. coli, His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 27.1 kDa and the accession number is P0C6H7.
|
|||||
TMPY-02193 | GOLPH2/GOLM1 Protein, Human, Recombinant (His) | Human | HEK293 Cells | ||
Golgi membrane protein 1, also known as Golgi membrane protein GP73, Golgi phosphoprotein 2, and GOLM1, is a protein that belongs to the GOLM1 / CASC4 family. GOLM1 is widely expressed. It is highly expressed in the colon, prostate, trachea, and stomach. It is expressed at a lower level in testis, muscle, lymphoid tissues, white blood cells, and spleen. It is predominantly expressed by cells of the epithelial lineage. GOLM1 is expressed at a low level in the normal liver. Expression significantly increases in virus (HBV, HCV) infected liver. Expression of GOLM1 does not increase in liver disease due to non-viral causes (alcohol-induced liver disease, autoimmune hepatitis). Increased expression in hepatocytes appears to be a general feature of advanced liver disease. In liver tissue from patients with adult giant-cell hepatitis (GCH), GOLM1 is strongly expressed in hepatocyte-derived syncytial giant cells. GOLM1 is constitutively expressed by biliary epithelial cells but not by hepatocytes.
|
|||||
TMPY-04567 | SRPK1 Protein, Human, Recombinant (His & GST) | Human | Baculovirus Insect Cells | ||
Serine / threonine-protein kinase SRPK1, also known as SFRS protein kinase 1, Serine/arginine-rich protein-specific kinase 1, SR-protein-specific kinase 1 and SRPK1, is a cytoplasm and nucleus protein that belongs to the protein kinase superfamily and CMGC Ser/Thr protein kinase family. Isoform 2 of SRPK1 is predominantly expressed in the testis but is also present at lower levels in heart, ovary, small intestine, liver, kidney, pancreas and skeletal muscle. Isoform 1 of SRPK1 is only seen in the testis, at lower levels than isoform 2. SRPK1 hyperphosphorylates RS domain-containing proteins such as SFRS1, SFRS2 and ZRSR2 on serine residues during metaphase but at lower levels during interphase. SRPK1 plays a central role in the regulatory network for splicing, controlling the intranuclear distribution of splicing factors in interphase cells and the reorganization of nuclear speckles during mitosis. SRPK1 locks onto SFRS1 to form a stable complex and processively phosphorylates the RS domain. SRPK1 appears to mediate HBV core protein phosphorylation which is a prerequisite for pregenomic RNA encapsidation into viral capsids.
|